600829.SH
人民同泰
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.22
−4.16%Year over year
Reported trailing growth
- Revenue
- +4.1%
- EBITDA
- —
- EBIT
- -17.8%
- EPS
- -24.5%
- Free cash flow
- +73.8%
- Operating cash flow
- +76.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2.5%
- EBITDA
- -16.1%
- EBIT
- -17.2%
- Net income
- -20.3%
- EPS
- -20.3%
- Free cash flow
- -2.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026